Central Street America

It’s funny what can bring you hope, sometimes it can be the simplest thing and yesterday it was, with the bonus of it happening on a picture perfect fall day.

Yes, Fall is finally here in the Midwest, the squirrels are crazy busy, school is back in session, and it is raining leaves! It’s once again that time of year when if you don’t have children to pick up after school you stay off the roads when the yellow buses swarm…stopping frequently (and holding up traffic) while their charges finally spill from the bus!

But sometimes household or work-related schedules must be met and even sans kids, you find yourself caught up in the after school mayhem. While it Continue reading→

COVID-19 Infection Increases the Risk of New or Worsening OAB Symptoms

Patients with COVID-19 infection are at increased risk of developing new or worsening symptoms of overactive bladder (OAB), according to data presented at the American Urological Association’s annual meeting in 2022 in New Orleans, Louisiana. Ly Hoang Roberts, MD, of Oakland University, Royal Oak, Michigan, and colleagues noted that they were the first American group to identify de novo genitourinary symptoms, such as frequency, urgency, nocturia, and pain / pressure in people with previous COVID 19 infection. They called this condition COVID-19 associated cystitis (CAC). Read more.

Source: Community 99, May 15, 2022

First Quality Introduces MaxSorb+ Zone For Bladder Control Pads

First Quality Products, Inc. is launching a new technology for bladder control pads called MaxSorb+ Zone, providing enhanced rapid absorption to help keep skin dry all day and support skin health. Pads that use First Quality’s MaxSorb+ Zone absorb up to 50% faster compared to previous Prevail bladder control pads. Read more.

Source: Nonwovens Industry, April 28, 2022

Simpler Surgery May Work As Well As Standard For Women With Incontinence

For women with frequent urine leakage, a newer and simpler “sling” surgery works as well as the standard version, according to a new clinical trial. The study involved women with stress urinary incontinence, where movement that puts pressure on the abdomen — such as running, lifting, coughing or laughing — causes urine leakage. When the condition is severe, surgery may be recommended. Read more.

Source: UPI, April 1, 2022

pelvic vaginal mesh stress urinary incontinence Polypropylene vaginal mesh

Newer Mesh Slings for Stress Incontinence a Safe, Effective Option for Women: Study

Source: HealthDay News, March 31, 2022

Medtronic Kicks Off Pivotal Study of Tibial Neuromodulation Implant for Overactive Bladder

After receiving an FDA approval last month in bladder and bowel incontinence for its neuromodulation device implanted in the lower back, Medtronic isn’t resting on its laurels. It has begun a clinical trial of a similar system placed near the ankle, which the company described as a more convenient option that may make the therapy available to more people. The medtech giant announced that its first patients have received implants in the pivotal study, with neurostimulators that tap into the posterior tibial nerve running up the back of the leg, to transmit electrical pulses that aim to help regulate an overactive bladder. Read more.

Source: Fierce Biotech, March 25, 2022

Renovia, ObvioHealth Conclude Fully Virtual Medical Device Trial in Urogynaecology

Virtual Research Organisation (VRO) ObvioHealth may have completed the first ever fully virtual urogynaecology study, in the form of a medical device clinical trial of Renovia’s digital intravaginal device Leva for female stress urinary incontinence. Urinary incontinence is unintentional passing of urine, which affects one in four women, particularly 75% of women above the age 65 reporting urine leakage. Pelvic floor muscle training (PMFT), commonly known as Kegels, is the standard among noninvasive approaches for urinary incontinence. However, 75% of women perform the exercises incorrectly by engaging wrong muscle groups or following a wrong routine. Leva is designed to help users how to preform Kegels more effectively. Read more.

Source: Clinical Trials Arena, March 17, 2022

Axonics® Receives FDA Approval for Recharge-Free Sacral Neuromodulation System

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has approved its newly developed, long-lived, recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS). Read more.

Source: Business Wire, March 7, 2022

Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902

Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced positive topline results from its Phase 2a, double-blind, placebo-controlled exploratory study of URO-902, an investigational, novel, locally injected gene therapy product (plasmid human cDNA encoding maxi-K channel), in patients with overactive bladder (OAB), who were not well managed by oral therapies. Read more.

Source: Pharmiweb.com, March 7, 2022

Tailoring Continence Management to Individual Needs in Residential Care

This observational study investigated the benefits of adopting a person-centred approach to the management of urinary incontinence and associated hygiene care. A trial was carried out in 12 residential care homes in the Emilia Romagna region of Italy. Toileting, containment product selection, frequency and timing of changes, and personal hygiene routines were tailored to the needs of individual residents. Skin redness improved, there was less leakage and residents’ wellbeing improved. Containment product changes were easier to carry out, fewer containment products were used, and product costs were reduced. The adoption of person-centred care initiatives was seen to benefit all stakeholders – namely, residents, caregivers and the administration of the residential care facility. Read more.

Source: Nursing Times, March 7, 2022